SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Amending Item 6 to file a corrected Exhibit 27.1)
(Mark One)
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 for the quarterly period ended September 30, 1998 or
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from _____ to _____.
Commission File Number: 333-22359
BIONX IMPLANTS, INC.
(Exact name of registrant as specified in its charter)
Delaware 22-3458598
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1777 Sentry Parkway West
Gwynedd Hall, Suite 400
Blue Bell, Pennsylvania 19422
(Address of principal executive office, including zip code)
215-643-5000
(Registrant's telephone number, including area code)
________________________________________________________________________________
(Former name, former address and former fiscal year, if changed since
last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No___
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
At November 3, 1998, there were 8,922,076 shares of Common Stock, par value
$.0019 per share, outstanding.
<PAGE>
Item 6. Exhibits and Reports on Form 8-K*
(a) The following exhibits are filed as part of this Quarterly Report on
Form 10-Q:
No. 27.1 Financial Data Schedule
(b) The Registrant did not file any Current Report on Form 8-K during the
quarter ended September 30, 1998.
*Items omitted from this Form 10-Q/A (Amendment No. 1) are either included in
the Registrant's Quarterly Report on Form 10-Q, as initially filed, or are not
applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this amended report to be signed on its behalf by the
undersigned thereunto duly authorized.
BIONX IMPLANTS, INC.
By: /s/David W. Anderson
David W. Anderson,
President and Chief Executive Officer
By: /s/ Michael J. O'Brien
Michael J. O'Brien
Vice President, Chief Financial Officer
and Chief Accounting Officer
Dated: November 19, 1998
<PAGE>
EXHIBIT INDEX
Exhibit No.
Exhibit No. 27.1 Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
(Replace this text with the legend)
</LEGEND>
<CIK> 0001030418
<NAME> BIONX IMPLANTS, INC.
<MULTIPLIER> 1000
<CURRENCY> U.S.
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-END> SEP-30-1998
<EXCHANGE-RATE> 1
<CASH> 17,069
<SECURITIES> 0
<RECEIVABLES> 4,087
<ALLOWANCES> 150
<INVENTORY> 6,339
<CURRENT-ASSETS> 28,584
<PP&E> 2,864
<DEPRECIATION> (646)
<TOTAL-ASSETS> 34,533
<CURRENT-LIABILITIES> 4,152
<BONDS> 0
0
0
<COMMON> 17
<OTHER-SE> 30,273
<TOTAL-LIABILITY-AND-EQUITY> 34,533
<SALES> 14,781
<TOTAL-REVENUES> 15,071
<CGS> 3,200
<TOTAL-COSTS> 10,880
<OTHER-EXPENSES> 93
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (822)
<INCOME-PRETAX> 1,720
<INCOME-TAX> 529
<INCOME-CONTINUING> 1,191
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,191
<EPS-PRIMARY> .13
<EPS-DILUTED> .13
</TABLE>
